Bioactive Food Components and Cancer-Specific Metabonomic Profiles by Kim, Young S. & Milner, John A.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 721213, 9 pages
doi:10.1155/2011/721213
Review Article
Bioactive FoodComponentsand Cancer-Speciﬁc
Metabonomic Proﬁles
Young S.Kim andJohn A. Milner
Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health,
Bethesda, MD 20892, USA
Correspondence should be addressed to Young S. Kim, yk47s@nih.gov
Received 16 June 2010; Revised 29 September 2010; Accepted 5 October 2010
Academic Editor: Olav Kvalheim
Copyright © 2011 Y. S. Kim and J. A. Milner. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Cancer cells possess unique metabolic signatures compared to normal cells, including shifts in aerobic glycolysis, glutaminolysis,
and de novo biosynthesis of macromolecules. Targeting these changes with agents (drugs and dietary components) has been
employed as strategies to reduce the complications associated with tumorigenesis. This paper highlights the ability of several food
components to suppress tumor-speciﬁc metabolic pathways, including increased expression of glucose transporters, oncogenic
tyrosine kinase, tumor-speciﬁc M2-type pyruvate kinase, and fatty acid synthase, and the detection of such eﬀects using various
metabonomic technologies, including liquid chromatography/mass spectrometry (LC/MS) and stable isotope-labeled MS. Stable
isotope-mediated tracing technologies oﬀer exciting opportunities for deﬁning speciﬁc target(s) for food components. Exposures,
especially during the early transition phase from normal to cancer, are critical for the translation of knowledge about food
components into eﬀective prevention strategies. Although appropriate dietary exposures needed to alter cellular metabolism
remain inconsistent and/or ill-deﬁned, validated metabonomic biomarkers for dietary components hold promise for establishing
eﬀective strategies for cancer prevention.
1.Introduction
Cancer cells exhibit unique metabolic signatures that are re-
quired for their aberrant proliferation [1]. Thus, monitoring
changes in small-molecular-weight compounds (metabo-
nomics) may represent an approach for detecting subtle
shifts in tumor cell behavior [2]. Consequently, metabo-
nomics holds promise as an eﬀective tool for diagnosing dis-
ease progression, for identifying potential molecular targets,
and for developing preventive and therapeutic agents (drugs
and bioactive food components) [3, 4].
The two most eﬀective approaches for metabonomic
measures include nuclear magnetic resonance (NMR) and
mass spectrometry (MS). Urine [5, 6], saliva [7], and blood
plasma [8] have all been used successfully to monitor
metabonomic patterns prior to and following intervention.
Currently, a wealth of information about metabonomics is
accumulating, thanks to highly sensitive Fourier transform
ioncyclotronresonanceMS(FT-ICRMS)[9,10]andreliable
candidate technologies such as stable isotope monitoring
[11].
Scientists have long recognized that the discovery
of novel and noninvasive biomarkers is fundamental to
designing eﬀective clinical studies, forecasting disease risk,
understanding how molecular pathways are interconnected
within cells and organisms, and ultimately predicting health.
For example, a change in serum lactate concentration, as
determined by 1H-NMR spectroscopy predicts weight gain
during chemotherapy and ultimately breast cancer recur-
rence risk [12]. Likewise, the elevated urinary prostaglandin
E(2) metabolite (11-α-hydroxy-9, 15-dioxo-2,3,4,5-tetranor-
prostane-1, 20-dioic acid) has been reported to predict a
poor prognosis in head and neck squamous cell carcinoma
patients and thus the need for more aggressive intervention
approaches [13]. Unfortunately, the relationship between a
given set of biomarkers and a particular pathological con-
dition is often complicated by adjustments and adaptations,
making the predictive value of such measures diﬃcult to2 Journal of Biomedicine and Biotechnology
establish. Metabonomic proﬁles of blood, urine, or tissues
reﬂecting in situ status of metabolites may provide a means
of identifying such biomarkers.
The annotation of metabolites identiﬁed by NMR- and
MS-based experiments remains a challenge due to the
diversityofstudyconditions.Thus,itisimportanttodevelop
a standardized format that allows the scientiﬁc community
to understand results from studies with widely diﬀerent
conditions. To facilitate this process, a working group of
the Metabolomics Standards Initiative was formed in 2004
[14]. This group has established guidelines for the exchange
and/or report of metabonomics data. Currently available
metabonomic databases, including NIST08, PubChem, and
KEGG, also help identify metabolite spectral data and
structural information. An extensive review of metabonomic
databases is found in a published paper [15]. Well-annotated
and user-friendly databases should be able to assist in
resolving unknown dietary metabolites that play a role in
cancer initiation and development.
Considerable evidence points to diet as a variable that
can inﬂuence cancer risk and/or tumor behavior [16]. This
dietary eﬀect may arise from its interactions with key
regulatory molecules in various cancer processes, including
carcinogen metabolism, hormonal balance, cell signaling,
cell cycle control, apoptosis, and diﬀerentiation. The goal of
this paper is to provide some insights into the metabonomic
assessment of dietary eﬀe c t so nc a n c e r .T h i si sc r i t i c a lt o
evaluate whether a single or multiple dietary component(s)
modulate the early transition phase from normal to cancer
phenotypes, including changes in speciﬁc enzymatic activi-
ties and carbon ﬂows.
2.Metabonomic Shifts Causedby Bioactive
Food Components in Cancer Cells
Metabolic proﬁling of cancer cells represents global pheno-
typic changes, including those in glucose metabolism, amino
acidmetabolism,andfattyacidmetabolism.Thissectiondis-
cusses diet-induced alterations in basic metabolism that are
associated with changes in cancer cell behavior and the mon-
itoring of those changes using global metabonomic proﬁles.
2.1. Glucose Metabolism. A distinct diﬀerence between nor-
mal and cancer cells lies in the way these cells utilize
glucose for their survival. The energy that sustains cancer
cells is preferentially derived from aerobic glycolysis, which
produces signiﬁcantly higher amounts of lactate from pyru-
vate, whereas normal cells use the aerobic tricarboxylic acid
(TCA) cycle, which oxidizes pyruvate to CO2 and water.
Furthermore, proliferating cancer cells also utilize glucose
for the synthesis of nucleotides through the nonoxidative
pentose phosphate pathway (PPP) and de novo fatty acid
synthesis mediated by fatty acid synthase (FAS) [1]. These
diﬀerences in metabolism between normal and cancer cells
are particularly interesting because they are detectable by
non-invasive proﬁling in blood or urine and thereby can
serve as clinically useful biomarkers for predicting diet-
induced shifts in the metabolic switch. Potential metabo-
nomic targets for bioactive food components are discussed
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Figure 1: Potential metabonomic targets for bioactive food com-
ponents during glucose metabolism in cancer cells. Cancer cells
metabolize glucose and glutamine more than normal cells to sup-
port the de novo biosynthesis of nucleotides and energy required for
the high rate of cell proliferation. Tumor-speciﬁc PKM2 determines
theratioofglucosemetabolismbetweenglycolysisandPPP,whereas
GLUT1andTKplaycriticalrolesinenergyproductioninneoplastic
cells via the TCA cycle and glutaminolysis, respectively. Each of
these pathways is modulated by speciﬁc bioactive food components
(see text). BFCs: bioactive food components; PKM2: pyruvate
kinase M2 isoform; PPP: pentose phosphate pathway; TK: tyrosine
kinase; GLUT1: glucose transporter 1; TCA: tricarboxylic acid.
in detail in the following sections and are summarized in
Figure 1.
2.1.1. Increased Glucose Uptake. Increased glucose uptake
is recognized as a hallmark for cancer cell malignancy
a n ds e r v e sa sab a s i sf o ru s i n g18F-deoxyglucose positron
emission tomography for cancer detection. Recently, a KRAS
mutation with aberrant cell proliferation was found to relate
to the upregulation of the glucose transporter (GLUT1)
gene, suggesting that genetic mutations acquired in tumor
cells account for enhanced glucose uptake [17]. This change
is critical for cell proliferation [18], and thus GLUT1
expression may represent a promising target for cancer
prevention. A number of dietary components, including
green tea polyphenolics, cinnamon polyphenol extracts, ﬁsh
n-3 fatty acids, and vegetable ﬂavonoids such as myricetin
andquercetin,havebeendocumentedasmodiﬁersofglucose
uptake by altering GLUT1 expression [19–22]. Impressively,
these eﬀects occur in several cell lines, suggesting widespread
utility of their beneﬁts. The concentrations used, at least
for some, appear physiologically relevant and therefore may
occur after a simple dietary change. Although these ﬁndings
provide promise for the diet-mediated prevention of cancer
cell proliferation, unfortunately none of these dietary eﬀects
was examined with high-throughput metabonomic proﬁles.
Considering the ability of metabonomics to detect changes
in glucose metabolism in cancer cells [23], it is likely that
these dietary eﬀects on glucose uptake, including GLUT1
expression, can be detected using the same approach.
2.1.2. Aerobic Glycolysis. The conversion of glucose to lactate
in the presence of oxygen is a critical aerobic pathway that
allows cancer cells to proliferate rapidly. In vivo expressionJournal of Biomedicine and Biotechnology 3
of the M2 isoform of the glycolytic enzyme pyruvate kinase
(PK) is required for this process [24]. PK has four isozymes
that are tissue speciﬁc: the L and R isoforms are expressed
in liver and red blood cells, respectively the M1 in most
adult tissues and M2 in lung and embryonic cells. In
normal proliferating cells, PK exists in a tetrameric form that
transfers one phosphate group from phosphoenolpyruvate
(PEP) to adenosyl diphosphate, yielding one molecule of
adenosine triphosphate (ATP). In cancer cells, however, this
enzyme is exclusively expressed as an M2 type of pyruvate
kinase (PKM2), which results in a conformational change
from a tetrameric to a dimeric form that possesses a low
aﬃnity for PEP and thus limits enzymatic function. This
structural change was shown to be mediated through phos-
photyrosine peptides or src in cancer cells [25], suggesting
that oncogenic tyrosine kinases (TKs) might be promising
targets for cancer prevention. Support for this conclusion
comes from observations that PKM2 is released from
tumors into the blood and can be monitored non-invasively.
Plasma tumor PKM2 is reported to increase signiﬁcantly as
tumor progresses in lung cancer, qualifying it as a valuable
biomarker[26].Recently,delphinidin,ananthocyanidinthat
is abundant in grapes, cranberries, and pomegranates, has
been reported to inhibit TK activities, including receptor
TKs [27]. Additionally, isothiocyanates in broccoli have
been reported to inhibit TK [28]. Overall, these ﬁndings
suggest that some of the antiproliferative eﬀects of bioactive
food components may arise from their ability to convert
tetrameric PKM2 to dimeric PKM2 and thereby bring about
a shift in glucose ﬂux from a nonoxidative to an oxidative
pathway. Although some evidence exists that changes in
glucose carbon ﬂux from glycolysis to gluconeogenesis can
be measured by the combination of LC/MS metabonomic
proﬁling with stable isotope techniques using 13C-labeled
glucose [29], these approaches have not been used for the
study examining dietary eﬀects. Thus, it is warranted to
use metabonomic proﬁling to monitor the eﬀects of diet
or dietary components on PKM2-mediated shifts in glucose
ﬂux.
Although limited numbers of metabonomic studies
have examined the cancer preventive eﬀects of dietary
components, the eﬃcacy of the dietary supplement silib-
inin provides some proof of principle. Silibinin, extracted
from a milk thistle, has been reported to signiﬁcantly
inﬂuence the metabolism of prostate cancer cells [30].
Quantitative high-resolution proton NMR spectroscopy
was used to monitor the metabonomic proﬁle of blood
and tissue extracts in non-human animals receiving or
not receiving silibinin. The metabolomic proﬁle suggested
that feeding TRAMP/C57BL/6 mice with a 1% silibinin-
supplemented diet reduced lactate formation, increased
glucose oxidation through the TCA cycle, reversed the
increase in citrate use, and decreased cholesterol and phos-
phatidylcholine levels in prostatic tumors, which parallels
earlier ﬁndings regarding the prostate cancer preventive
potential of silibinin in this animal model. These results
suggest that non-invasive metabolomic studies can help
monitor the eﬀectiveness of cancer preventives against
malignancy.
2.1.3. Increased De Novo Biosynthesis of Nucleotides via the
Pentose Phosphate Pathway. Since PKM2 in cancer cells does
not convert PEP to pyruvate eﬃciently, the upstream glucose
metabolites are redirected towards a biosynthetic pathway
such as PPP. Any rapidly proliferating cells, including
cancer cells, utilize PPP to generate ribose-5-phosphate and
the reduced form of nicotinamide adenine dinucleotide
phosphate (NADPH) from glucose, which is essential for
de novo DNA formation. Evidence exists that vitamin E,
which is abundant in wheat germ extract and various
other fat sources, inhibits nonoxidative tumor cell PPP and
thereby suppresses cancer cell proliferation [31]. In leukemia
patients, vitamin E was found to decrease pentose cycle
substrate ﬂow into RNA ribose, which was measured using
stable isotope-labeled [1,2-13C2] glucose as the single tracer
and biological MS. These changes in glucose carbon ﬂux
correlated with the cell growth-controlling and apoptosis-
inducing eﬀects of fermented wheat germ [31].
Another dietary component, genistein, which is found
in soy, has also been shown to exhibit a similar eﬀect on
PPP without modulating fatty acid synthesis [32]. When
MIA pancreatic cancer cells were treated with a physiological
concentrationofgenistein(20μM)for3days,thecarbonﬂux
from 13C-labeled glucose to nucleic acid ribose through the
nonoxidativePPPdecreasedsigniﬁcantly[32].Thesechanges
in PPP coincided with the cancer protective eﬀects of either
vitamin E or genistein, implying that a shift in a metabolic
signature may be a useful biomarker for monitoring the
eﬃcacy of dietary components.
2.2. Amino Acid and Fatty Acid Metabolism
2.2.1. Glutaminolysis. Glucose is the major energy source
in normal cells. This nutrient undergoes the metabolic
switch in tumor cells from energy production to de novo
biosynthesis of macromolecules, including nucleic acids.
This shift increases the demand for carbon sources in cancer
cells to generate ATP. It has been reported that cancer cells
accumulate glutamine faster than noncancerous cells [33]
and utilize it as a substrate for the TCA cycle (glutaminol-
ysis). Ultimately, the cancer cell catabolizes glutamine to
ATP and lactate. This metabolic shift is thought to be
mediated bythe myc oncogene [34].Itis wellestablished that
the activity of this oncogene can be modulated by various
dietary components, including betaine, folic acid, genistein,
and fat [35–38]. For example, supplementing the diet with
betaine (1%) fed to rats developing liver tumors caused by
diethylinitrosamine signiﬁcantly reduced liver c-myc expres-
sion [35]. 1H-NMR spectroscopy-based metabolic proﬁles
of plasma and urine have revealed an interaction between
betaine exposure and low-density lipoprotein receptor gene
expression [39]. Metabonomic proﬁles that explore the
inﬂuence of dietary fat metabolism regulators to detect
variation in c-myc oncogene expression are warranted.
2.2.2. Fatty Acid Synthase. Treatment of mouse mammary
epithelial cells (HC11) in culture with 40nM of genistein
for 6 hours has been reported to signiﬁcantly suppress4 Journal of Biomedicine and Biotechnology
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Figure 2: Fatty acid synthase as a metabonomic target for
bioactive food components in cancer cells. Tumor cells exhibit
the increased activity of FAS, which converts citrate-originated
acetyl-CoA to fatty acids, mainly palmitate. The citrate is generated
in mitochondria and, instead of further oxidation, is exported
to cytosol as citrate. Upon exit, citrate forms acetyl CoA and is
converted to fatty acids in cytosol, which is suppressed by a variety
of dietary components, including tea catechin, DHA in ﬁsh oil,
β-glucan in barley and mushrooms, resveratrol in red grapes, the
vegetable ﬂavonoid luteolin, and CLA in milk. FAS: fatty acid
synthase; CoA: coenzyme A; PUFA: polyunsaturated fatty acid;
DHA: docosahexaenoic acid; CLA: conjugated linoleic acid.
Wnt-1-induced, but not basal, expression of c-Myc [37]. It
is logical that several dietary components may aﬀect myc
gene expression in vivo to regulate glutaminolysis, and this
issue should be clariﬁed using metabonomics. In tumor
cells, the limited aﬃnity of tumor-speciﬁc PKM2 for PEP
forces some, but not all, pyruvates to be oxidized to citrate
in the mitochondria. This citrate is then exported to the
cytosol, where it is used as a substrate for fatty acid synthesis
(Figure 2). This shift from oxidation to lipogenesis in citrate
metabolism is evident by the increased activity of FAS,
which converts glucose-originated malonyl-CoA to long-
chain fatty acids, mainly palmitate, in tumor cells. The
synthesized fatty acids are incorporated into phospholipids,
the accumulation of which may cause metabolic diseases,
including cancer. For example, the de novo biosynthesis of
fatty acids from glucose as determined by proton NMR
spectroscopy (1H-MRS) is frequently observed with the lipid
droplet formation in brain tumor glioma cells [40]. The
possibility that these synthesized fatty acids may modulate
the oncogenic PI3K/AKT pathway and thereby inﬂuence
glucose uptake and metabolism cannot be ignored.
A variety of dietary components, including tea catechin,
docosahexaenoic acid (DHA) in ﬁsh oil, β-glucan in barley
and mushrooms, resveratrol in red grapes, the vegetable
ﬂavonoid luteolin, and conjugated linoleic acid in milk, have
been shown to suppress FAS expression and activity [41–46].
T r e a t m e n to ft h eh u m a nb r e a s tc a n c e rc e l lS KB r - 3 ,w h i c h
constitutively expresses FAS, with 150μM epigallocatechin-
3-gallate (EGCG) for 24 hours resulted in a marked
reduction in this enzyme activity (59%±13%), but not its
expression, compared to controls [41]. In the same study, the
suppressive eﬀect of EGCG on FAS activity was conﬁrmed
in vivo using C57BL/6J male mice. Likewise, the oral
feeding of C57BL/KsJ-db/db mice with DHA (1g DHA/100g
diet) for 4 weeks signiﬁcantly reduced hepatic FAS activity
accompanied by lowered levels of triglyceride [42]. Finally,
feeding C57BL mice a high-fat diet supplemented with
4% barley containing a high amount of β-glucan for 12
weeks signiﬁcantly reduced the hepatic FAS activity [43]. It
should be possible to detect diet-induced changes in FAS
with metabolomic proﬁling, which allows the monitoring of
changes in physiologic enzyme activities using LC/MS [47].
The responsiveness of FAS to dietary components, the
diﬀerential expression of this enzyme in various stages of
cancer development, and its critical role in de novo lipid
synthesis made it an ideal target for the dietary prevention
of cancer. It has been shown that altered FAS expression
brings about the signature metabolic changes in human
prostate cancer. Human prostatic epithelial cells are highly
unique in accumulating zinc that blocks citrate degradation.
In cancer cells, however, the prostate tissue contains low
levels of citrate, because it does not accumulate zinc and
because most of the citrate is used for fatty acid synthesis.
1H-MRS of prostate tissues conﬁrmed the dramatic decrease
in citrate levels in prostate gland during malignancy [30].
Likewise,silibinininmilkthistlewasreportedtosigniﬁcantly
decrease the expression of FAS and its transcription factor,
sterol response element-binding protein 1c, as examined
with 1H-MRS-based metabonomic approaches in neoplastic
prostate cells [30]. The metabolic proﬁle of prostatic tumors
obtained from TRAMP mice fed a silibinin diet for 20
weeks revealed decreases in lactate and increases in citrate.
Thus, a shift in the metabolic proﬁle may help explain
silibinin’s antitumorigenic eﬀects. Fatty acid synthesis is also
known to be inﬂuenced by several confounding factors,
including peroxisome proliferator-activated receptors and
choline availability [48]. Metabonomic proﬁles of tissue
extracts may provide important clues about the fatty acid
homeostasis that is likely to be inﬂuenced by multiple
variables, including dietary habits.
3.Stable Isotope Technologies
The activity of bioactive food components in the body is
dynamic, and thus a single point in time measurement
may not lead to appropriate conclusions. Fortunately, these
subtle shifts in metabolites can be traced using labels,
including stable isotopes. Stable isotopes such as 13Co r
15N that generate mass diﬀerence and thus can be detected
by NMR or imaging technologies are widely used to trace
dynamic movements, including nutrient ﬂux, bioavailability,
or kinetics in vivo [49]. Other major advantages of stable
isotopes include their stability and independency, which
allows long-term studies as well as the simultaneous labeling
of more than one molecule on the same compound.
Although stable isotope technologies combined with
NMR, especially 2D 1H total correlation spectroscopy, can
be used for correlating a single isotopomer to its parental
compound, the resolving power and sensitivity of this
analytical technique are much less than those of MS.
Stable isotope labeling, combined with various types of
MS equipped with versatile ion sources such as FT-ICR,
electrospray,andmatrix-assistedlaserdesorption/ionization,Journal of Biomedicine and Biotechnology 5
Table 1: Preclinical and clinical nutrition studies using stable-isotope metabonomics.
Specimen Analysis Stable
isotope Results Reference
Blood, urine NMR, GC-MS 13C
Diﬀerential glucose metabolic pathways between normal and cancer
cells in lung: 13C glucose was infused to lung cancer patients and
showed enhanced production of Asp and Glu via glycolysis in lung
tumor tissues.
Fan et al.
[50]
Cell extracts GC/MS 13C
The treatment of MIA pancreatic adenocarcinoma cells with 200μM
genistein for 3 days reduced the glucose (labeled with [1,2-13C]
glucose) metabolism via the nonoxidative pentose pathway, which
coincided with its antiproliferative eﬀects.
Boros et al.
[32]
Cell extracts GC-MS 13C The altered ﬂux in response to gluconeogenic substrates in fasting rat
hepatocytes was measured with [1,2-13C2] glucose.
Marin et
al. [51]
Cell extracts GC-MS 13C
The treatment of butyrate-sensitive HT29 human colon
adenocarcinoma cells with 5mM butyrate resulted in the inhibition
of glucose uptake, oxidation, and nucleic acid ribose synthesis.
Boren et
al. [52]
Plasma GC/MS 13C The hypoglycemia seen in the fasting PPARα null mouse is due to the
reduced recycling of glucose carbon from lactate back to glucose.
Xu et al.
[53]
Table 2: Metabonomic proﬁles of metabolites from selected bioactive food components in human blood and urine.
Food source Component Metabonomic
analysis Blood Urine Reference
Green tea EGCG HPLC-MS/MS EGCG
Sulfated and glucuronidated
conjugates of EGCG, hippuric
acids
D e lR i oe ta l .[ 58]W a n g
JS et al. [59].
Soy Genistein LC-ESI-MS/MS Monoglucuronides of
genistein Glucuronidated genistein Guy et al. [60]K a n oe t
al. [61].
Cruciferous
vegetables Glucobrassicin HPLC-MS/MS DIM, LTr1, H1-1M DIM Reed et al. [62]
Anderton et al. [63].
Red grapes Piceid
LC-MS/MS,
NMR,
HPLC/DAD
Sulfate and
glucuronide
conjugates of
transresveratrol
Sulfate and glucuronide
conjugates of trans-resveratrol
Burkon and Somoza
[64]., Boocock et al.
[65].
Cruciferous
vegetables Glucoraphanin HPLC-MS, LC-
(ESI)MS/MS Sulforaphane
Mercapto-conjugates of
sulforaphane (N-acetyl cysteine
conjugates are major
metabolites.)
Egner et al. [66], Al
Janobi et al. [67].
Fish,
Mushroom Vitamin D2,D 3 LC-MS/MS 25-OH vitamin D 24,25(OH)2D3,
1α,24,25(OH)2D3
van den Ouweland et al.
[68].
can isolate and detect the molecule of interest—even when
several compounds may be crowded at one location on the
proﬁle—and thus serves as a powerful tracing technique.
Representative preclinical and clinical studies using stable
isotope technologies involving nutrition and cancer are
provided in Table 1 [50–53]. Several excellent reviews about
the merits of stable isotopes have been recently published
[11, 54].
4.MetabonomicsCanDetectCancer
PreventiveDietaryMetabolitesGenerated
by Microorganisms
It seems obvious that the biological functions of small-
molecular-weight compounds (metabolites) are modulated
by microbiota accounting for more than 100 trillion living
organisms in the human gut. Gastrointestinal microbes
are quick responders to dietary changes in terms of their
metabolism and/or gene expression. Evidence exists that
these changes may aﬀect the utility of nutrients obtained
from the diet and thereby inﬂuence human health and
disease outcome [55]. The precise role of microbes in
physiological metabolic pathways was investigated using a
well-deﬁned animal model transplanted with human fecal
microbial communities [55]. When these animals were fed
a high-fat and high-sugar diet (Harlan-Teklad TD96132),
they developed increased adiposity, which can be char-
acterized metabolically when switched to a low-fat and
plant-polysaccharide-rich diet (B&K 7378000) [55]. These
results suggest that microbes may either provide additional6 Journal of Biomedicine and Biotechnology
metabolicpathwaystothehostordirectlymodifytheexisting
processes, resulting in altered phenotypes. Speciﬁc examples
of how microbes metabolize dietary components and release
cancer preventive compounds are described in detail in an
earlier review [56]. With the current advances in “omics”
technologies, these changes caused by human gut microbes
can be directly detected by metabolomic proﬁles [57].
Although the application of metabolomics to microbiome
projects is in its infant stage, the eﬀects of diet on the human
gut microbiome and the utilization of metabolomic analysis
for its detection hold promise for future investigation.
5. Metabonomics InvolvingBioactiveFood
Components inClinicalStudies
The current status of metabonomics that has been used for
identifying and characterizing the physiological metabolites
of food ingredients in humans is summarized in Table 2
[58–68]. The analysis of active food metabolites usually has
been conducted with compounds known to be eﬃcacious
to human diseases. The molecules that interact with cellular
components of target tissues are not food constituents but
rather their metabolites that are absorbed and transported
to each site of action [69–71]. For example, EGCG, which
occurs in green tea, is considered to be a tumor preventive
agent. Nevertheless, the prostate tissue of men who had
consumed 6 cups of green tea daily for 6 weeks contained
both EGCG and its methylated metabolite 4  -O-methyl
EGCG. The latter has been reported to be less active than
EGCG in terms of its cancer preventive action [69]. On the
other hand, urolithin, a microbially generated metabolite of
an active component in pomegranate juice, ellagic acid, has
been found to exhibit cancer protection in various tissues,
including colon, breast, and prostate [70, 71]. Thus, ﬁndings
from metabonomic studies should be able to assist with
clarifying how food or dietary components are metabolized
in the body, possibly modulate human cell behavior, and
ultimately and possibly inﬂuence human health. Currently,
limited numbers of investigations exist in this area, but the
science is poised to provide important new insights.
6. FutureDirections
Metabonomics is the systematic study of small-molecular-
weight substances that are the ﬁnal products of genes and
proteins. Although extensive research about genomics and
proteomics is beginning to unravel the role of genes and
proteins, the metabolites that dictate their characteristics for
a given phenotype remain largely ill-deﬁned. Metabonomic
proﬁling using readily available bioﬂuids, tissue extracts, or
intact tissues may provide early clues about cellular events
that inﬂuence phenotypic characteristics. Recently, there has
been increased interest in cancer metabonomics and its
potential for use in clinical and/or epidemiological investi-
gations. The enriched understanding of basic mechanisms
that account for shifts in the metabolome should become
reality for metabonomic investigations so that eﬀective
interventions can be employed.
Although nutrition is known to modulate a number
of regulatory networks involved with pathways leading to
and promoting cancer, there is a dearth of studies that
have examined diet as an important variable. Admittedly,
there are critical issues in understanding metabonomic
proﬁling information from nutritional studies, including
the quantity and the temporal relationship of the bioactive
food component consumed. Regardless, the fundamental
nature of nutrition in harnessing overall cellular metabolism
deserves greater attention. Controlled human intervention
studies that incorporate physiologically relevant concentra-
tions and exposures for various times are fundamental to the
understanding of the utility of metabonomics as a tool for
predicting phenotypic change caused by diet. Although there
will be many challenges to the interpretation of these studies,
their societal implications are enormous given the central
rolethatdiethasinhealthpromotionanddiseaseprevention,
especially that related to cancer.
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